Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Galapagos has temporarily stopped enrolling patients into an early-phase test in patients with multiple myeloma after a neurological issue was raised. Elsewhere, the biotech expanded
Agios’ first-ever pediatric data readout missed the primary endpoint, with its drug Pyrukynd (mitapivat) not showing statistical significance in children with pyruvate kinase (PK) deficiency
Ken Song is back in business. He left RayzeBio in February after leading the radiopharmaceuticals startup from Series A to IPO in three years, and
Rare disease specialist Ultragenyx reeled in a $14 million seed round for its Alzheimer’s gene therapy spinout Amlogenyx, the company exclusively told Endpoints News. …
Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS
Mark Boucot has his signs ready. “The signs that will be hung around my facility [will] say ‘It is a federal crime to commit a
An artificial intelligence (AI)-powered handheld ultrasonography device operated by novice users estimated gestational age as accurately as credentialed sonographers using ultrasound equipment, a prospective diagnostic
PHILADELPHIA — Blood biomarkers specific to Alzheimer’s disease — specifically, amyloid-beta 42/40 ratios and measures of phosphorylated tau 181 (p-tau181) — had a relationship with
The FDA expanded the approval of dostarlimab (Jemperli) plus chemotherapy for primary advanced or recurrent endometrial cancer to include patients with mismatch repair proficient/microsatellite stable